MDR1について
MDR1（multidrug resistance protein 1、P糖蛋白質）は、小腸、血液脳関門などに分布し、細胞の中からプラスチャージ（カチオン）の薬剤を排泄します。抗癌剤の薬剤耐性因子としても、注目されています。
＜ヒトMDR1との薬剤相互作用が引き起こす副作用＞
| 薬 |
阻害剤/誘導剤 |
効果および毒性 |
作用機序 |
| Loperamide |
Quinidine |
Increased CNS adverse effects |
MDR1の機能阻害 |
| Talinolol |
Verapamil |
Decreased plasma levels |
MDR1の機能阻害 |
| Fexofenadine |
Erythromycin |
Increased plasma levels |
MDR1の機能阻害 |
| Fexofenadine |
Rifampin |
Decreased plasma levels |
MDR1の機能阻害 |
| Digoxin |
Quinidine |
Increased plasma levels and
decreased renal clearance |
MDR1の機能阻害 |
| Digoxin |
Verapamil |
Increased plasma levels and
decreased renal clearance |
MDR1の機能阻害 |
| Digoxin |
Talinolol |
Increased plasma levels and
decreased renal clearance |
MDR1の機能阻害 |
| Digoxin |
Clarithromycin |
Increased plasma levels and
decreased renal clearance |
MDR1の機能阻害 |
| Digoxin |
Statins |
Increased plasma levels and
decreased renal clearance |
MDR1の機能阻害 |
| Digoxin |
Rifampin |
Decreased plasma levels |
MDR1の誘導 |
参考文献Ho RH and Kim RB, Transporters and drug therapy: implications for drug disposition and disease.Clin Pharmacol Ther. 2005;78(3):260-77. Review.
|
